JP2008531699A - 骨障害の治療 - Google Patents

骨障害の治療 Download PDF

Info

Publication number
JP2008531699A
JP2008531699A JP2007558120A JP2007558120A JP2008531699A JP 2008531699 A JP2008531699 A JP 2008531699A JP 2007558120 A JP2007558120 A JP 2007558120A JP 2007558120 A JP2007558120 A JP 2007558120A JP 2008531699 A JP2008531699 A JP 2008531699A
Authority
JP
Japan
Prior art keywords
antibody
bone
mammal
drug
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007558120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531699A5 (enExample
Inventor
ケー． リー シューエル，
ジョアン クワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36941715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008531699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008531699A publication Critical patent/JP2008531699A/ja
Publication of JP2008531699A5 publication Critical patent/JP2008531699A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007558120A 2005-02-28 2006-02-28 骨障害の治療 Withdrawn JP2008531699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65694305P 2005-02-28 2005-02-28
PCT/US2006/006998 WO2006093923A2 (en) 2005-02-28 2006-02-28 Treatment of bone disorders

Publications (2)

Publication Number Publication Date
JP2008531699A true JP2008531699A (ja) 2008-08-14
JP2008531699A5 JP2008531699A5 (enExample) 2009-03-19

Family

ID=36941715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007558120A Withdrawn JP2008531699A (ja) 2005-02-28 2006-02-28 骨障害の治療

Country Status (16)

Country Link
US (1) US20060263355A1 (enExample)
EP (1) EP1856157A2 (enExample)
JP (1) JP2008531699A (enExample)
KR (1) KR20070114196A (enExample)
CN (1) CN101166764A (enExample)
AR (1) AR054427A1 (enExample)
AU (1) AU2006218733A1 (enExample)
BR (1) BRPI0608109A2 (enExample)
CA (1) CA2597097A1 (enExample)
IL (1) IL185052A0 (enExample)
MX (1) MX2007010307A (enExample)
NO (1) NO20074911L (enExample)
RU (1) RU2007135878A (enExample)
TW (1) TW200714289A (enExample)
WO (1) WO2006093923A2 (enExample)
ZA (1) ZA200707280B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528949A (ja) * 2013-06-21 2016-09-23 デピュイ・シンセス・プロダクツ・インコーポレイテッド フィルム及び製造方法
US10617653B2 (en) 2011-12-28 2020-04-14 DePuy Synthes Products, Inc. Films and methods of manufacture
US10814112B2 (en) 2005-10-13 2020-10-27 DePuy Synthes Products, Inc. Drug-impregnated encasement
JP2023549237A (ja) * 2020-11-10 2023-11-22 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7833270B2 (en) * 2006-05-05 2010-11-16 Warsaw Orthopedic, Inc Implant depots to deliver growth factors to treat osteoporotic bone
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
WO2009018411A1 (en) * 2007-07-31 2009-02-05 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
US8345282B2 (en) * 2007-08-03 2013-01-01 Kyocera Document Solutions Inc. Image forming system and image forming apparatus
US8153112B2 (en) 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
WO2009048780A1 (en) * 2007-10-08 2009-04-16 The University Of Kentucky Research Foundation Polymer-metal chelator conjugates and uses thereof
US20100272696A1 (en) * 2007-12-21 2010-10-28 Bone Therapeutics S.A. Human Bone-Forming Cells In The Treatment of Inflammatory Rheumatic Diseases
MX2010008148A (es) 2008-01-25 2010-10-20 Chimerix Inc Métodos de tratamiento de infecciones virales.
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2210615A1 (en) * 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
CA2981549A1 (en) * 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010279678B2 (en) * 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP6174320B2 (ja) 2009-11-17 2017-08-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトヌクレオリンに対するヒトモノクローナル抗体
AU2010324686B2 (en) * 2009-11-30 2016-05-19 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
WO2011100698A2 (en) 2010-02-12 2011-08-18 Chimerix, Inc. Methods of treating viral infection
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN103153352B (zh) 2010-08-18 2015-07-15 爱默蕾大学 用于骨化的化合物和组合物以及其相关的方法
CN109432502A (zh) * 2011-04-25 2019-03-08 南加州大学 一种用于修复头盖缺陷的植入物
US20150148292A1 (en) * 2012-07-09 2015-05-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PL3312195T3 (pl) * 2013-03-20 2020-04-30 Genzyme Corporation Sposoby leczenia wrodzonej łamliwości kości
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
CN111709446B (zh) * 2020-05-14 2022-07-26 天津大学 基于改进的密集连接网络的x线胸片分类装置
CN112274302B (zh) * 2020-11-24 2021-07-13 四川大学华西医院 一种多单元可调的智能化椎间融合器
CA3226401A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
CN113398270B (zh) * 2021-07-20 2023-04-25 中国科学院上海营养与健康研究所 一种治疗骨巨细胞瘤的方法
CN121022731A (zh) * 2025-10-28 2025-11-28 苏州大学 单样本来源破骨细胞与成骨细胞的同步分化方法及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4256833A (en) * 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
AT359652B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4271070A (en) * 1980-05-05 1981-06-02 Cornell Research Foundation, Inc. Chemically-modified fiber collagen hemostatic agents
US4761471A (en) * 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
ATE20824T1 (de) * 1981-06-25 1986-08-15 Serapharm Gmbh & Co Kg Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung.
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4928603A (en) * 1984-09-07 1990-05-29 The Trustees Of Columbia University In The City Of New York Method of preparing a cryoprecipitated suspension and use thereof
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5716413A (en) * 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
FR2786182B1 (fr) * 1998-11-24 2001-01-12 Hoechst Marion Roussel Inc Nouveaux derives d'acylguanidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
KR20020027311A (ko) * 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US6673771B1 (en) * 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU6788900A (en) * 1999-09-03 2001-04-10 Amgen, Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1263933A2 (en) * 2000-02-18 2002-12-11 Rhode Island Hospital Treatment for bone disorders
US7074408B2 (en) * 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
IL151906A0 (en) * 2000-03-24 2003-04-10 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
DK1272647T3 (en) * 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
ES2706902T3 (es) * 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
US20030015708A1 (en) * 2001-07-23 2003-01-23 Primit Parikh Gallium nitride based diodes with low forward voltage and low reverse current operation
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10814112B2 (en) 2005-10-13 2020-10-27 DePuy Synthes Products, Inc. Drug-impregnated encasement
US10617653B2 (en) 2011-12-28 2020-04-14 DePuy Synthes Products, Inc. Films and methods of manufacture
JP2016528949A (ja) * 2013-06-21 2016-09-23 デピュイ・シンセス・プロダクツ・インコーポレイテッド フィルム及び製造方法
US10500304B2 (en) 2013-06-21 2019-12-10 DePuy Synthes Products, Inc. Films and methods of manufacture
JP2023549237A (ja) * 2020-11-10 2023-11-22 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物
JP7575598B2 (ja) 2020-11-10 2024-10-29 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物

Also Published As

Publication number Publication date
IL185052A0 (en) 2007-12-03
AU2006218733A1 (en) 2006-09-08
BRPI0608109A2 (pt) 2009-11-03
TW200714289A (en) 2007-04-16
WO2006093923A2 (en) 2006-09-08
CA2597097A1 (en) 2006-09-08
CN101166764A (zh) 2008-04-23
EP1856157A2 (en) 2007-11-21
MX2007010307A (es) 2007-10-12
WO2006093923A8 (en) 2007-09-07
NO20074911L (no) 2007-11-27
AR054427A1 (es) 2007-06-27
RU2007135878A (ru) 2009-04-10
KR20070114196A (ko) 2007-11-29
ZA200707280B (en) 2008-12-31
WO2006093923B1 (en) 2007-06-28
US20060263355A1 (en) 2006-11-23
WO2006093923A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
JP2008531699A (ja) 骨障害の治療
TWI433682B (zh) Cd20抗體於治療多發性硬化症之用途及用於該用途之物品
JP2008538767A (ja) Ｃｄ２０抗体による認知症又はアルツハイマー病の治療方法
JP2008507555A (ja) シェーグレン症候群の治療方法
JP2008501706A5 (enExample)
JP2008501706A (ja) 疾患の治療方法
US20060233797A1 (en) Treatment of inflammatory bowel disease (IBD)
JP2008515890A (ja) 血管炎の治療方法
EP2231183A2 (en) Therapy of rituximab-refractory rheumatoid arthritis patients
US20090269339A1 (en) Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
HK1114864A (en) Treatment of bone disorders
HK1148473A (en) Therapy of rituximab-refractory rheumatoid arthritis patients
HK1103669A (en) Method of treating sjorgren's syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090127

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100730